Synergistic effect of dual chamber pacing and disopyramide in obstructive hypertrophic cardiomyopathy

International Journal of Cardiology

Volumn 141, Issue 2, 2010, Pages 195-197

  Minami, Yuichiro ^a   Kajimoto, Katsuya ^a   Kawana, Masatoshi ^a   Hagiwara, Nobuhisa ^a   Sherrid, Mark V ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Disopyramide; Dual chamber pacing; Hypertrophic cardiomyopathy

Indexed keywords

DISOPYRAMIDE;

ADULT; AORTA PRESSURE; ARTICLE; ARTIFICIAL HEART PACEMAKER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; EQUIPMENT DESIGN; FEMALE; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART PACING; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; PRIORITY JOURNAL;

ANTI-ARRHYTHMIA AGENTS; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; COMBINED MODALITY THERAPY; DISOPYRAMIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 77952239329     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.088     Document Type: Article

References (13)

1. Maron M.S., Olivotto I., Betocchi S., et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348 (2003) 295-303
2. Pollick C. Disopyramide in hypertrophic cardiomyopathy. II. Noninvasive assessment after oral administration. Am J Cardiol 62 (1988) 1252-1255
3. Pollick C., Kimball B., Henderson M., and Wigle E.D. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration. Am J Cardiol 62 (1988) 1248-1251
4. Sherrid M., Delia E., and Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 62 (1988) 1085-1088
5. Sherrid M.V., Barac I., McKenna W.J., et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 45 (2005) 1251-1258
6. Fananapazir L., Epstein N.D., Curiel R.V., Panza J.A., Tripodi D., and McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 90 (1994) 2731-2742
7. Kappenberger L., Linde C., Daubert C., et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC study group. Eur Heart J 18 (1997) 1249-1256
8. Maron B.J., Nishimura R.A., McKenna W.J., Rakowski H., Josephson M.E., and Kieval R.S. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 99 (1999) 2927-2933
9. Nishimura R.A., Trusty J.M., Hayes D.L., et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 29 (1997) 435-441
10. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42 (2003) 1687-1713
11. Nagueh S.F., Ommen S.R., Lakkis N.M., et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38 (2001) 1701-1706
12. Maron B.J. Surgery for hypertrophic obstructive cardiomyopathy: alive and quite well. Circulation 111 (2005) 2016-2018
13. Seggewiss H., Gleichmann U., Faber L., et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol 31 (1998) 252-258